Dose Insider / FDA warning letters / Synthetix Inc. DBA Helix Chemical Supply

Synthetix Inc. DBA Helix Chemical SupplyFDA warning letter, February 7, 2024

FDA letter of February 7, 2024 · posted February 13, 2024 · checked against fda.gov on November 20, 2026

On February 7, 2024, FDA sent Synthetix Inc. DBA Helix Chemical Supply of Bronx, NY, a warning letter saying that helixchem.com offered semaglutide and tirzepatide that FDA considers unapproved new drugs.

4 sectionsof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024, this letter11202573202678FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024, this letter11202573202678

16 letters are of the same kind as this one: other matters, such as a clinical investigator or a supplement.

On this page

The letter notes that products were labeled for research use only or not for human consumption.

FDA posted the letter on February 13, 2024. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanySynthetix Inc. DBA Helix Chemical Supply
LocationBronx, NY
Website namedhelixchem.com
Letter datedFebruary 7, 2024
Posted by FDAFebruary 13, 2024
Issuing officeCenter for Drug Evaluation and Research | CDER
FDA’s subject lineUnapproved New Drugs/Misbranded
Drugs namedsemaglutide and tirzepatide
Kind of letterOther
Reply asked within15 working days
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 668918

What did FDA quote?

The letter quotes 6 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

Which parts of the law did FDA cite?

The letter cites 4 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
502(f)(1)A drug is misbranded if its labeling lacks adequate directions for use33
505(a)A new drug may not be sold across state lines without an approved application48
301(a)It is prohibited to introduce an adulterated or misbranded drug into interstate commerce142
301(d)It is prohibited to introduce a drug into interstate commerce in violation of section 50548

What did FDA ask the company to do?

In the letter’s own words:

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 115 of the 164 letters name tirzepatide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (1004 words)

February 7, 2024

RE: 668918

Dear Matthew Lucks:

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States. As described below, your “Semaglutide” and “Tirzepatide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “Semaglutide” and “Tirzepatide” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

Despite statements on your product labeling marketing your products for “research use only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body. Examples of claims from the products’ labeling, including as observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:

From your website www.helixchem.com:

Semaglutide

“Dose Amounts

Each vial contains:

Weeks 1-4 – 8 doses (reconstituted vial expires after 8 weeks.)

Weeks 5-8 – 8 doses (reconstituted vial expires after 8 weeks.) . . .

Semaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.”

Tirzepatide

“Dose Amounts

Each vial contains:

Weeks 1-4 – 4 doses

Weeks 5-8 – 2 doses. . .

Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality.”

From the “Standard Dose Protocol for Tirzepatide Research” document accompanying Tirzepatide:

“If additional glycemic control is needed. . . This is the standard schedule for the medication, Mounjaro.”

Unapproved New Drugs

Your “Semaglutide” and “Tirzepatide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Misbranded Drugs

Your “Semaglutide” and “Tirzepatide” products are also misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for their intended use(s). “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended, 21 C.F.R. 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1), include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Your “Semaglutide” product is indicated for a condition that is not amenable to self-diagnosis and treatment by a layperson, therefore adequate directions cannot be written such that a layperson can use the product safely for its intended use. In addition, your “Semaglutide” and “Tirzepatide” products are also prescription drugs as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. For these reasons, your “Semaglutide” and “Tirzepatide” products are misbranded under section 502(f)(1) of the FD&C Act.

The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

Conclusion

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.

Sincerely,

/S/

CAPT Tina Smith

Director

Office of Unapproved Drugs and Labeling Compliance

Center for Drug Evaluation and Research

Food and Drug Administration

Content current as of:

02/13/2024

Regulated Product(s)

Drugs

Sources

  1. FDA. Warning letter to Synthetix Inc. DBA Helix Chemical Supply, February 7, 2024 (MARCS-CMS 668918). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider